Antibody Therapy Market Analysis

Antibody Therapy Market Analysis

To get key market trends

  Download Free Sample

The market based on type is segmented into monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). The monoclonal antibodies (mAbs) segment is further split into oncology, autoimmune diseases, infectious diseases, and other monoclonal antibodies. The mAbs segment is expected to exhibit 11.7% CAGR during the forecast period.
 

• The segment dominance is majorly attributed to the increasing application of mAbs for the chronic diseases such as cancer, infection, genetic diseases, and others.
   
• mAbs as biologic products obtains several immune-mediated reactions and responses which increases the efficiency of the therapy.
   
• Also, mAbs are synthesized using recombinant biotechnology and progress in protein engineering, recombinant DNA technology, and various other platforms for generating different types of antibodies based on novel strategies, resulting in future segment market growth of antibody therapy over forecast period.

The antibody therapy market based on end-use is categorized into hospitals, specialty centers, and other end-users. The hospitals segment held the major share of 47.6% in 2022.
 

• The dominance of the hospital segment in the market is attributed to its role as a primary healthcare provider for severe and chronic diseases. Hospitals are equipped with specialized infrastructure, skilled personnel, and advanced technology required for administering and monitoring antibody therapies.
   
• Additionally, hospitals serve as hubs for critical care and emergency situations, making them epicenter in the treatment of disease conditions. This concentration ensures efficient delivery and management of these therapies, reinforcing the hospitals' pivotal role in the market.
   

The North America antibody therapy market is expected surpass the revenue USD 284.0 billion. by 2032.
 

• The region robust regulatory framework, rising investment in novel antibody therapy development by key players are few of the factors predicted to propel regional market growth. For instance, in August 2023, BARDA has partnered with Regeneron under 'Project NextGen' to aid the development and regulatory process of an advanced COVID-19 monoclonal antibody therapy, aiming to prevent SARS-CoV-2 infection. The collaboration involves clinical development and manufacturing support to accelerate the progress of innovative COVID-19 vaccines and treatment.
   
• Further, the presence of key market players, extensive healthcare facilities, and a proactive approach to adopting innovative treatments further solidify North America's prominence in the antibody therapy sector.